```html

Yolk‑Colored Vitreous (Vitreous Hemorrhage) – A Patient‑Friendly Guide

Overview

A vitreous hemorrhage occurs when blood leaks into the vitreous humor—the clear, jelly‑like substance that fills the interior of the eye behind the lens. When the blood is fresh, it often appears yellow‑orange, reminiscent of a yolk, which is why clinicians sometimes describe it as “yolk‑colored vitreous.” The condition can range from a few specks of blood that settle out on their own to a dense, vision‑obscuring pool that requires urgent treatment.

• Who it affects: Adults over 50 are most commonly affected because age‑related changes (e.g., proliferative diabetic retinopathy, retinal tears) increase the risk. However, younger adults with trauma, sickle‑cell disease, or blood‑coagulation disorders can also develop a vitreous hemorrhage.
• Prevalence: In the United States, vitreous hemorrhage accounts for roughly 1–2% of all ophthalmic emergency visits, translating to an estimated 200,000–300,000 cases annually.<sup>[1] CDC, 2022</sup>

Symptoms

Symptoms can appear suddenly or develop gradually, depending on the cause and the amount of blood.

• Sudden loss of vision or “shadow” across part of the visual field – often described as a curtain or veil that falls over the eye.
• Floaters – numerous tiny specks or threads that drift across the field of view; they may be yellow‑orange in color when fresh blood is present.
• Blurred or hazy vision – especially when the hemorrhage is dense.
• Red‑tinted vision (chromatopsia) – a subtle red or pink hue may be seen.
• Pain – usually mild; severe eye pain suggests another problem (e.g., angle‑closure glaucoma) and warrants immediate evaluation.
• Photophobia – sensitivity to light.
• Peripheral vision loss – more common when the bleed is located near the edge of the vitreous cavity.

Causes and Risk Factors

Primary Causes

• Proliferative diabetic retinopathy (PDR) – new, fragile blood vessels grow on the retina and can rupture.
• Retinal tears or detachments – tears allow blood to escape into the vitreous.
Ocular trauma – blunt or penetrating injuries can damage retinal vessels.
• Sickle‑cell disease – vaso‑occlusive crises can cause retinal ischemia and bleeding.
• Retinal vein occlusion – blockage of retinal veins leads to hemorrhage.
• Age‑related macular degeneration (neovascular AMD) – abnormal vessels under the retina may bleed.
• Inflammatory conditions – such as uveitis, which can cause leaky vessels.
• Blood‑clotting disorders – e.g., hemophilia, thrombocytopenia, or use of anticoagulant medications.

Risk Factors

• Long‑standing diabetes mellitus (especially with poor glycemic control).
• High myopia (severe nearsightedness) – stretches retinal tissue, increasing tear risk.
• History of ocular surgery (e.g., cataract extraction) – may predispose to retinal breaks.
• Systemic hypertension.
• Use of anticoagulants (warfarin, direct oral anticoagulants) or antiplatelet agents (aspirin, clopidogrel).
• Family history of retinal vascular disease.

Diagnosis

Prompt and accurate diagnosis is essential to preserve vision.

Clinical Examination

• Visual acuity test – assesses the degree of vision loss.
• Slit‑lamp biomicroscopy – provides a magnified view of the anterior segment and posterior vitreous.
• Fundus examination (indirect ophthalmoscopy) – allows the eye‑care provider to see the retina through the vitreous; the yolk‑colored blood may obscure details.

Imaging & Tests

• B‑scan ultrasonography – especially useful when the hemorrhage is dense and the retina cannot be visualized directly. It helps detect retinal detachments or foreign bodies.
• Optical coherence tomography (OCT) – offers high‑resolution cross‑sectional images of the retina; may be limited by media opacity but useful once the blood begins to clear.
• Fluorescein angiography (FA) – performed after the hemorrhage resolves enough to view retinal vessels; identifies neovascularization or leak sources.
• Blood work – when systemic causes are suspected (e.g., complete blood count, coagulation profile, HbA1c for diabetes).

Treatment Options

Treatment depends on the underlying cause, the amount of blood, and how quickly vision is affected.

Conservative Management

• Observation – Small, peripheral hemorrhages often clear spontaneously within 4–6 weeks. Patients are instructed to avoid vigorous activity and keep follow‑up appointments.
• Postural positioning – Tilting the head upright can help blood settle inferiorly, improving central vision while it clears.
• Control of systemic disease – Strict glycemic control for diabetics, blood pressure management, and cessation of smoking.

Medical Therapies

• Intravitreal anti‑VEGF injections (e.g., bevacizumab, ranibizumab) – Used when neovascularization (common in PDR or AMD) is the source of bleeding.
• Intravitreal steroids – Reserved for inflammatory vitreous hemorrhage (e.g., uveitis).

Surgical Interventions

• Pars plana vitrectomy (PPV) – The gold‑standard procedure for dense hemorrhages that do not clear or when a retinal tear/detachment is present. The surgeon removes the vitreous gel and blood, repairs retinal breaks, and may inject a tamponade gas or oil.
• Laser photocoagulation – Applied after the hemorrhage clears to seal retinal tears or ablate neovascular tissue.
• Scleral buckling – Occasionally combined with PPV for complex retinal detachments.

Lifestyle & Supportive Measures

• Protect eyes with safety glasses during high‑risk activities.
• Maintain a balanced diet rich in omega‑3 fatty acids and antioxidants (leafy greens, fish) to support retinal health.
• Adhere to medication regimens for diabetes, hypertension, and hyperlipidemia.

Living with Yolk‑Colored Vitreous (Vitreous Hemorrhage)

Daily Management Tips

• Vision adaptation – Use high‑contrast fonts, bright lighting, and magnifiers for reading.
• Safe navigation – Keep living spaces clear of tripping hazards; consider a cane or guide dog if peripheral vision is significantly reduced.
• Regular follow‑up – Appointments every 1–2 weeks initially, then spaced out as the eye clears.
• Medication adherence – Never skip anti‑VEGF injections or oral medications prescribed for systemic disease.
• Emotional health – Vision loss can cause anxiety or depression; seek counseling or support groups if needed.
• Driving considerations – Do not drive if vision is impaired; arrange alternative transportation.

Prevention

• Control diabetes – Keep HbA1c <7% (or as directed by your physician). Regular eye exams every 6–12 months can catch proliferative changes early.<sup>[2] ADA, 2023</sup>
• Manage blood pressure – Aim for <130/80 mmHg; untreated hypertension worsens retinal vessel fragility.
• Regular comprehensive eye exams – Especially for high‑risk groups (diabetics, high myopes, patients with prior retinal disease).
• Protective eyewear – Use safety glasses during sports, DIY projects, or when operating machinery.
• Limit anticoagulant dose when possible – Discuss with your physician the safest therapeutic range.
• Quit smoking – Smoking accelerates vascular damage and impairs healing.

Complications

If left untreated or inadequately managed, vitreous hemorrhage can lead to serious outcomes.

• Permanent vision loss – Persistent blood can cause retinal scarring (proliferative vitreoretinopathy).
• Retinal detachment – Blood may tractionally pull the retina away.
• Glaucoma – Blood may block the trabecular meshwork, raising intra‑ocular pressure.
• Neovascular glaucoma – New vessels form on the iris and angle structures in response to chronic ischemia.
• Sympathetic ophthalmia – A rare autoimmune response that can affect the fellow eye after severe trauma.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Ophthalmic Emergency Department Visits, United States, 2017–2021. CDC; 2022.
2. American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1‑S350.
3. Mayo Clinic. Vitreous hemorrhage. Updated 2024. https://www.mayoclinic.org/diseases‑conditions/vitreous‑hemorrhage
4. Cleveland Clinic. Vitreous Hemorrhage: Causes, Symptoms, and Treatment. 2023.
5. National Eye Institute, NIH. Proliferative Diabetic Retinopathy. 2022.
6. World Health Organization. Global Report on Vision 2022. WHO; 2022.

```